Saturday 17 October 2026 Export DTIL’s income statement to Excel — free account

Precision BioSciences, Inc.

Precision BioSciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $34.3 million, down 50.1% from fiscal 2024. In the quarter to June 2026, revenue grew 37,272.4%, EPS grew 40.9%, free cash flow grew 33.7% and total debt was flat, each against the same quarter a year earlier. Insiders bought in the last twelve months.

5.77 0.40 −6.48%

Follow DTIL

Alert me

Market cap: $170.3M
P/E: 0.0×
Fwd P/E: −2.6×
Dividend yield: —
F-score: 1/9
Altman Z: −4.31
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.06

Total sells 0.47

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	3	—	—	—	—	—	—	—	—	3	—
Sell	3	—	4	4	—	—	—	—	—	—	—	—

Insider Ownership 7.72%

Capital & Financial Ratios $m

Market Cap 170.30

Revenue 45.07

Net Income (52.73)

Free Cash Flow (52.32)

Net Debt (65.13)

Current Ratio 12.82

Debt/Equity 0.50

P/E ratio 0.00

Fwd P/E (2.59)

P/S ratio 3.31

P/B ratio 3.29

Past 5Y EPS Growth —

This Y EPS Growth (0.96%)

Next Y EPS Growth 20.98%

Next Y revenue growth (60.66%)

Next 5Y EPS Growth 17.58%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 43.16%

10-year low 10-year high

P/B against its own 10 years 64.47%

10-year low 10-year high

EV/Sales against its own 10 years 9.58%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	117	86	116	88
Receivables	1	0	—	—
Inventory	—	—	—	—
Other	1	2	0	0
	136	95	119	92

	2023	2024	2025	Q'26
Payables	3	1	0	1
ST’ Debt	—	—	—	—
Other	2	1	1	1
	50	15	9	7

Compound Annual Growth %

	10y	5y	3y
Sales	—	7.13%	10.93%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	15.74%	15.14%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	11	—	—	—	—
’25	0	0	0	34	34
’24	18	50	1	1	69
’23	9	20	13	7	49
’22	3	4	7	11	25
’21	16	69	24	6	116
’20	7	1	7	9	24

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(12)	(13)	—	—	—
’25	(19)	(20)	(15)	(11)	(66)
’24	(19)	(15)	(6)	(19)	(58)
’23	(31)	(21)	(23)	(8)	(84)
’22	(29)	(24)	29	(22)	(46)
’21	68	(31)	(24)	(24)	(11)
’20	(26)	(26)	(22)	(13)	(87)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(12)	(13)	—	—	—
’25	(19)	(20)	(15)	(12)	(66)
’24	(19)	(15)	(6)	(19)	(59)
’23	(32)	(22)	(24)	(8)	(86)
’22	(30)	(25)	28	(22)	(49)
’21	67	(33)	(25)	(25)	(17)
’20	(27)	(28)	(23)	(15)	(92)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.75)	(1.26)	—	—	—
’25	(2.21)	(2.13)	(1.84)	1.05	(3.56)
’24	1.70	4.67	(2.25)	(2.22)	1.04
’23	(6.91)	(3.00)	(2.10)	(4.06)	(15.96)
’22	(13.81)	(13.81)	(6.61)	(7.81)	(38.14)
’21	(9.91)	10.81	(5.71)	(11.41)	(15.62)
’20	(15.62)	(18.92)	(15.01)	(13.21)	(62.76)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	187.20	133.65	219.00	28.50	8.25	3.61	4.02	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	710.10	452.10	498.00	235.50	43.50	19.43	8.82
People
People	Employees	—	—	127	199	184	45	198	109	108	68
	Revenue/emp, $m	0.00	0.00	0.09	0.11	0.13	2.57	0.13	0.45	0.64	0.50
Income, $m
Income, $m	Revenue	7	6	11	22	24	116	25	49	69	34
	Gross margin, %	0.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00
	EBT	(8)	(21)	(46)	(93)	(109)	(31)	(73)	(43)	7	(47)
	EBT margin, %	(117.69)	(325.45)	(423.02)	(417.65)	(448.86)	(26.49)	(290.50)	(87.28)	10.43	(136.03)
	Net income	(8)	(21)	(46)	(93)	(109)	(31)	(112)	(61)	7	(46)
	Depreciation	1	2	2	5	10	10	9	8	4	2
Per share, $
Per share, $	Revenue	0.14	12.24	20.72	15.90	14.02	59.12	8.57	12.69	10.05	2.67
	Earnings	(0.16)	(39.84)	(87.63)	(66.37)	(62.76)	(15.62)	(38.14)	(15.96)	1.05	(3.56)
	Cash flow	1.84	(45.63)	(98.46)	(50.79)	(50.43)	(5.55)	(15.62)	(21.90)	(8.55)	(5.13)
	Capex	0.00	(10.41)	(27.15)	(17.64)	(2.90)	(2.97)	(1.13)	(0.57)	(0.03)	(0.05)
	Free cash flow	1.84	(56.04)	(125.62)	(68.43)	(53.34)	(8.52)	(16.75)	(22.46)	(8.58)	(5.18)
	Book value	(0.09)	(49.78)	76.07	98.92	25.64	46.65	20.63	4.91	8.25	7.19
	Shares, m	50	1	1	1	2	2	3	4	7	13
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.97	0.00
	P/S	25.25	25.25	25.25	26.20	17.85	3.76	4.10	0.88	0.38	1.56
	P/B	6.88	6.88	6.88	4.21	9.76	4.76	1.70	2.26	0.46	0.58
	EV/Sales	15.77	15.77	15.77	18.07	14.51	2.53	(2.57)	(1.45)	(0.55)	(1.16)
	EV/FCF	(2.60)	(2.60)	(2.60)	(4.20)	(3.81)	(18.40)	1.31	0.82	0.65	0.60
Cash, $m
Cash, $m	Operating cash flow	92	(24)	(52)	(71)	(87)	(11)	(46)	(84)	(58)	(66)
	Capex	(2)	(6)	(14)	(25)	(5)	(6)	(3)	(2)	0	(1)
	Free cash flow	92	(30)	(66)	(96)	(92)	(17)	(49)	(86)	(59)	(66)
Balance, $m
Balance, $m	Working capital	86	55	102	167	63	126	139	86	80	110
	Total debt	—	—	—	—	9	2	22	—	22	22
	Net debt	(93)	(63)	(103)	(181)	(81)	(141)	(167)	(117)	(64)	(93)
	Shareholders’ equity	(5)	(26)	40	138	44	91	60	19	56	92
Returns, %
Returns, %	ROA	(9.64)	(24.67)	(43.58)	(49.69)	(56.57)	(16.92)	(49.65)	(30.82)	4.84	(31.45)
	ROIC	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	53.02	135.60	(677.86)	(104.20)	(119.30)	(45.14)	(147.28)	(154.66)	19.05	(61.52)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Mar 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
PEPG PepGen, Inc.	$175.2M	— (loss-making)	—	—	n/m	+33.02% (above 0%: growing)	0.00%	0.00%	Compare
ORMP Oramed Pharmaceuticals Inc.	$173.9M	1.0×	— (loss-making)	+193.26% (above 0%: growing)	+493.75% (above 0%: growing)	+94.29% (above 0%: growing)	0.65%	0.00%	Compare
WHWK Whitehawk Therapeutics, Inc.	$173.3M	— (loss-making)	— (loss-making)	+33.48% (above 0%: growing)	n/m	+72.57% (above 0%: growing)	89.36%	0.00%	Compare
DTIL Precision BioSciences, Inc.	$170.3M	— (loss-making)	— (loss-making)	+37,272.41% (above 0%: growing)	n/m	+33.73% (above 0%: growing)	100.00%	0.00%
CHRS Coherus Oncology, Inc.	$165.3M	— (loss-making)	— (loss-making)	+39.53% (above 0%: growing)	n/m	−33.15% (below 0%: shrinking)	70.35%	(225.98%)	Compare
IPHA Innate Pharma S.A. Sponsored ADR	$165.3M	— (loss-making)	—	+246.29% (above 0%: growing)	+106.08% (above 0%: growing)	−929.03% (below 0%: shrinking)	0.00%	0.00%	Compare
VRXA Veraxa Biotech AG	$162.5M	—	—	—	—	—	—	—	Compare
CMPX Compass Therapeutics, Inc.	$161.5M	— (loss-making)	— (loss-making)	—	n/m	−26.05% (below 0%: shrinking)	100.00%	0.00%	Compare
ADAG Adagene Inc. Sponsored ADR	$161.1M	— (loss-making)	— (loss-making)	—	—	−11.08% (below 0%: shrinking)	—	—	Compare
Median of peers	$165.3M	—	—	+116.40%	—	−11.08%	35.50%	0.00%

All 614 Biotechnology stocks →

Precision BioSciences, Inc. (DTIL) key facts

Concern: Precision BioSciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $34.3 million, down 50.1% from fiscal 2024.
Precision BioSciences, Inc. (DTIL) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, DTIL traded at $5.77, a market capitalization of $170.3 million.
Return on equity was −61.5% and debt-to-equity 0.50.
Its Piotroski F-score is 1 out of 9 and its Altman Z-score is −4.31 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.